Medical/Pharmaceuticals News & Press Release Distribution

Medical/Pharmaceuticals

APAC
Global

GCAM Adds New Plasma Collection Center

FULLERTON, Calif. and YONGIN, South Korea, Jan. 10, 2020 /PRNewswire/ -- GCAM, Inc., a U.S. based plasma collection company, announced that it has added additional plasma collection centers; located inEdinburg, Texas. With the newest additions, GCAM now runs 12 plasma donation centers nationwide....

2020-01-10 22:00 1629

VolitionRx Completes Acquisition of Octamer GmbH

AUSTIN, Texas, Jan. 10, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the closing of the acquisition of the epigenetic reagent company Octamer GmbH ("Octamer") by its subsidiary Belgian Volition SPRL for approximately$725,000, consisting of cash and sh...

2020-01-10 21:00 14891

VISTA Eye Specialist bringing vision correction to a whole breakthrough level of safety

KUALA LUMPUR, Malaysia, Jan. 10, 2020 /PRNewswire/ -- VISTA Eye Specialist (VISTA), one of the premier and largest eye specialist inMalaysia, announces the introduction of No-Blade ICL, a combination of the Ziemer LDV Z8 Femtosecond Laser and the Visian EVO ICL. Placed within the eye, the ICL hel...

2020-01-10 17:32 3205

VISTA Eye Specialist bringing vision correction to a whole breakthrough level of safety

Cala Health Applauded by Frost & Sullivan for Revolutionizing the Essential Tremor Market with its Body-worn Neuromodulation Therapy, Cala Trio(TM)

SANTA CLARA, Calif., Jan. 9, 2020 /PRNewswire/ -- Based on its recent analysis of the North American essential tremor (ET) treatment market, Frost & Sullivan recognizes Cala Health, Inc. with the 2019 North American Technology Innovation Award for its Cala Trio™, a prescription-only, wrist-worn d...

2020-01-09 22:00 922

Cala Health Applauded by Frost & Sullivan for Revolutionizing the Essential Tremor Market with its Body-worn Neuromodulation Therapy, Cala Trio(TM)

WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases

* The 12th global licensing partnership for WuXiBody™ since its launch in August 2018 showcasing the power and versatile applications of WuXiBody™ in multiple therapeutic areas SHANGHAI and BARCELONA, Spain, Jan. 9, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global o...

2020-01-09 17:10 2283

Alma, a Sisram Medical Company, Launches DermaClear 3-in-1 Skin Hydradermabrasion Platform

NUREMBERG, Germany, Jan. 9, 2020 /PRNewswire/ -- Alma, one of the top five global leaders of energy-based medical and aesthetic solutions, today announced the launch of DermaClear, a powerful 3-in-1 treatment solution for deep cleansing, nourishment, and hydration of facial skin. DermaClear i...

2020-01-09 17:00 1507

Alma, a Sisram Medical Company, Receives Excellence Award for "Outstanding Business Performance in Japan"

NURNBERG, Germany, Jan. 9, 2020 /PRNewswire/ -- Alma, one of the top five global leaders of energy-based medical and aesthetics solutions, today announced it has been recognized with an Excellence Award for its "outstanding business performance inJapan" in 2019. The annual "Excellence Award" was...

2020-01-09 10:00 1225

Daewoong Infion obtained World's First Halal Certification for Biopharmaceutical Product Derived from Animal Cells

SEOUL, South Korea, Jan. 9, 2020 /PRNewswire/ -- Daewoong Infion Co. has achieved world's first halal certification for animal cells-derived biopharmaceuticals. World's First Halal certification for Biopharmaceutical Product derived from An...

2020-01-09 09:51 2798

Daewoong Infion obtained World's First Halal Certification for Biopharmaceutical Product Derived from Animal Cells

Publication of a Toxicological Study: A Milestone for Jennewein Biotechnologie for the GRAS Approval of the HMO-mix

RHEINBREITBACH, Germany, Jan. 9, 2020 /PRNewswire/ -- Jennewein Biotechnology announces another milestone in the worldwide approval of a new product generation, the "HMO-Mix." The data of the toxicological study, with the title "A Safety Evaluation of Mixed Human Milk Oligosaccharides in Rats," w...

2020-01-09 02:26 2251

Symmetry Surgical, Inc. Acquires The O.R. Company

Acquisition strengthens Symmetry's commitment to deliver best-in-class, cost-effective solutions NASHVILLE, Tennessee, Jan. 9, 2020 /PRNewswire/ -- Symmetry Surgical, Inc. ("Symmetry"), is pleased to announce that it has completed its acquisition of The O.R. Company. The O.R. Company develops, m...

2020-01-09 00:37 1185

Waters Corporation Lauded by Frost & Sullivan for Developing the First Truly Smart Mass Spectrometer, the BioAccord LC-MS System

The system was designed to enhance productivity, positioning the user to acquire and process data with a purpose-built LC-MS platform SANTA CLARA, California, Jan. 8, 2020 /PRNewswire/ -- Based on its analysis of the global biopharmaceutical analytical instrumentation market, Frost & Sullivan ...

2020-01-08 21:30 6146

Waters Corporation Lauded by Frost & Sullivan for Developing the First Truly Smart Mass Spectrometer, the BioAccord LC-MS System

Transcenta Holding Secures $100 Million Series B Plus Financing

HONG KONG and SUZHOU and HANGZHOU, China, Jan. 8, 2020 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, R&D, and manufacturing of antibody-based therapeutics, announces today that it has sealed a 100 millio...

2020-01-08 21:00 1339

Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors

SHANGHAI and PHILADELPHIA, Jan. 8, 2020 /PRNewswire/ -- The Antengene board today announced the appointment of Mr.Mark J. Alles as an independent director of the company, effectiveJanuary 2, 2020. Mr. Alles is the former Chairman and Chief Executive Officer of Celgene Corporation, now a subsidiar...

2020-01-08 20:00 2829

Connect Biopharma Reports Positive Topline Data from Moderate-to-severe Atopic Dermatitis (AD) Phase 1b Study of CBP-201

Data show superior efficacy after four weeks of treatment and more rapid onset of action for CBP-201 compared with data from studies of current standard of care therapy for AD On Day 29, 42.9% and 50.0% of patients receiving CBP-201 300 mg or 150 mg, respectively, achieved "clear/almost clear" s...

2020-01-08 19:00 935

CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma

SUZHOU, China, Jan. 8, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) announced that the first patient has been dosed in the Phase III GEMSTONE-304 study of the Company's anti-PD-L1 antibody CS1001 in combination therapy as first-line treatment in patients wit...

2020-01-08 13:45 2712

Daewoong Pharmaceutical Receives World's First Halal Certification for Biopharmaceutical Product Derived from Animal Cells through Indonesian Joint Venture, Daewoong Infion

SEOUL, South Korea, Jan. 8, 2020 /PRNewswire/ -- Daewoong Infion Co. has achieved world's first halal certification for animal cells-derived biopharmaceuticals. Daewoong Pharmaceutical Co., Ltd. (CEO Sengho Jeon) announced that Daewoong Infion, the company's joint venture with Infion, an In...

2020-01-08 11:00 1159

Hummingbird Bioscience Publishes Preclinical Data Demonstrating Efficacy of HMBD-001 in HER3 Driven Cancers

* HER3 activation is implicated in tumor progression and in acquired resistance to EGFR and HER2 therapies * Study, published in Molecular Cancer Therapeutics, found HMBD-001 to be able to uniquely block HER3 dimerization interface and potently inhibit tumor growth SINGAPORE, Jan. 8, 2020 /PR...

2020-01-08 10:40 748

Rapid Diagnostics Announces Completion of Asset Purchase and New Corporate Strategies

LONDON, Jan. 8, 2020 /PRNewswire/ -- Rapid Diagnostics ML Limited, UK is pleased to announce the return of its Point of Care (PoC) platform, the MiniLab System. Rapid was formed to purchase the assets and Intellectual Property (IP) of the former Enigma Diagnostics, which was liquidated in 2017. ...

2020-01-08 08:00 1934

Innovent and Sirnaomics Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US

SUZHOU, China, Jan. 8, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, and Sirnaomics Inc. ("Si...

2020-01-08 08:00 8764

Rising Demand for IoT-enabled Pumps to Drive North American PD Pumps Market amid Economic Slowdown

Integration of machine learning, artificial intelligence in pumps to help improve efficiency and reduce maintenance costs, finds Frost & Sullivan SANTA CLARA, California, Jan. 8, 2020 /PRNewswire/ -- Driven by continued investments in the US oil and gas industry, along with increased activity in ...

2020-01-08 06:03 988

1 ... 529 530 531532533 534 535 ... 577